NRX PHARMACEUTICALS INC (NRXP) Fundamental Analysis & Valuation

NASDAQ:NRXP • US6294442099

Current stock price

2.95 USD
-0.08 (-2.64%)
At close:
2.9227 USD
-0.03 (-0.93%)
After Hours:

This NRXP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NRXP Profitability Analysis

1.1 Basic Checks

  • In the past year NRXP has reported negative net income.
  • In the past year NRXP has reported a negative cash flow from operations.
  • NRXP had negative earnings in each of the past 5 years.
  • NRXP had a negative operating cash flow in each of the past 5 years.
NRXP Yearly Net Income VS EBIT VS OCF VS FCFNRXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -220.92%, NRXP is not doing good in the industry: 92.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -220.92%
ROE N/A
ROIC N/A
ROA(3y)-440.47%
ROA(5y)-508.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXP Yearly ROA, ROE, ROICNRXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • NRXP's Gross Margin of 58.78% is fine compared to the rest of the industry. NRXP outperforms 67.54% of its industry peers.
  • NRXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRXP Yearly Profit, Operating, Gross MarginsNRXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NRXP Health Analysis

2.1 Basic Checks

  • NRXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NRXP has more shares outstanding
  • NRXP has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for NRXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRXP Yearly Shares OutstandingNRXP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
NRXP Yearly Total Debt VS Total AssetsNRXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -36.93, we must say that NRXP is in the distress zone and has some risk of bankruptcy.
  • NRXP's Altman-Z score of -36.93 is on the low side compared to the rest of the industry. NRXP is outperformed by 92.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.93
ROIC/WACCN/A
WACC9.56%
NRXP Yearly LT Debt VS Equity VS FCFNRXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 0.31 indicates that NRXP may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.31, NRXP is doing worse than 95.29% of the companies in the same industry.
  • NRXP has a Quick Ratio of 0.31. This is a bad value and indicates that NRXP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NRXP's Quick ratio of 0.31 is on the low side compared to the rest of the industry. NRXP is outperformed by 93.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.31
NRXP Yearly Current Assets VS Current LiabilitesNRXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NRXP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.32% over the past year.
EPS 1Y (TTM)55.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NRXP will show a very strong growth in Earnings Per Share. The EPS will grow by 50.85% on average per year.
  • NRXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 182.54% yearly.
EPS Next Y129.65%
EPS Next 2Y77.66%
EPS Next 3Y90.76%
EPS Next 5Y50.85%
Revenue Next Year169.49%
Revenue Next 2Y575.21%
Revenue Next 3Y352.07%
Revenue Next 5Y182.54%

3.3 Evolution

NRXP Yearly Revenue VS EstimatesNRXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
NRXP Yearly EPS VS EstimatesNRXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. NRXP Valuation Analysis

4.1 Price/Earnings Ratio

  • NRXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 9.64, the valuation of NRXP can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NRXP indicates a rather cheap valuation: NRXP is cheaper than 87.96% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.99. NRXP is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.64
NRXP Price Earnings VS Forward Price EarningsNRXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXP Per share dataNRXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • NRXP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NRXP's earnings are expected to grow with 90.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y77.66%
EPS Next 3Y90.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRXP Dividend Analysis

5.1 Amount

  • NRXP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NRXP Fundamentals: All Metrics, Ratios and Statistics

NRX PHARMACEUTICALS INC

NASDAQ:NRXP (4/28/2026, 5:43:18 PM)

After market: 2.9227 -0.03 (-0.93%)

2.95

-0.08 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-23
Earnings (Next)05-13
Inst Owners25.16%
Inst Owner Change0%
Ins Owners5.39%
Ins Owner Change0%
Market Cap97.56M
Revenue(TTM)1.23M
Net Income(TTM)-28.62M
Analysts84
Price Target38.76 (1213.9%)
Short Float %10.72%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-423.64%
Min EPS beat(2)-476.7%
Max EPS beat(2)-370.59%
EPS beat(4)1
Avg EPS beat(4)-216.35%
Min EPS beat(4)-476.7%
Max EPS beat(4)31.37%
EPS beat(8)3
Avg EPS beat(8)-118.76%
EPS beat(12)6
Avg EPS beat(12)-73.23%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.86%
Min Revenue beat(2)-96.52%
Max Revenue beat(2)-87.19%
Revenue beat(4)0
Avg Revenue beat(4)-95.93%
Min Revenue beat(4)-100%
Max Revenue beat(4)-87.19%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.4%
PT rev (3m)3.4%
EPS NQ rev (1m)20%
EPS NQ rev (3m)20%
EPS NY rev (1m)140%
EPS NY rev (3m)-65.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-71.81%
Revenue NY rev (3m)-71.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.64
P/S 79.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)0.31
Fwd EY10.37%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.04
BVpS-0.48
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -220.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.78%
FCFM N/A
ROA(3y)-440.47%
ROA(5y)-508.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.31
Altman-Z -36.93
F-Score6
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.44%
EPS Next Y129.65%
EPS Next 2Y77.66%
EPS Next 3Y90.76%
EPS Next 5Y50.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year169.49%
Revenue Next 2Y575.21%
Revenue Next 3Y352.07%
Revenue Next 5Y182.54%
EBIT growth 1Y17.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.52%
EBIT Next 3Y167.38%
EBIT Next 5Y110.47%
FCF growth 1Y-32.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.67%
OCF growth 3YN/A
OCF growth 5YN/A

NRX PHARMACEUTICALS INC / NRXP Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NRX PHARMACEUTICALS INC (NRXP) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NRXP.


What is the valuation status of NRX PHARMACEUTICALS INC (NRXP) stock?

ChartMill assigns a valuation rating of 4 / 10 to NRX PHARMACEUTICALS INC (NRXP). This can be considered as Fairly Valued.


How profitable is NRX PHARMACEUTICALS INC (NRXP) stock?

NRX PHARMACEUTICALS INC (NRXP) has a profitability rating of 1 / 10.


What is the expected EPS growth for NRX PHARMACEUTICALS INC (NRXP) stock?

The Earnings per Share (EPS) of NRX PHARMACEUTICALS INC (NRXP) is expected to grow by 129.65% in the next year.